Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: A-101 Clear all
Completed Not applicable Interventional

Biofeedback-VR for Treatment of Chronic Migraine

NCT05720819
View directory record Official record
Conditions
Chronic Migraine, Behavioral Treatment, Biofeedback, Virtual Reality, Medication Overuse Headache
Interventions
Combined biofeedback-virtual reality device
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 2, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis

NCT03148691
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
A-101
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Miami, Florida • Newnan, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2019 · Synced Sep 2, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.

NCT02667236
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
A-101 Solution, Vehicle Solution
Drug · Other
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Sep 2, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of A-101 Solution in Subjects With Common Warts.

NCT02669862
View directory record Official record
Conditions
Common Warts
Interventions
A-101 Solution 40, A-101 Solution 45, Vehicle Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Wayne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 2, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

NCT02160626
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
A-101 Vehicle, A-101 (40) Topical Solution, A-101 (32.5) Topical Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
5
States / cities
Snellville, Georgia • Clinton Township, Michigan • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Sep 2, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

NCT03278028
View directory record Official record
Conditions
Common Wart
Interventions
A-101 Topical Solution, A-101 Vehicle Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
8 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
16
States / cities
Glendale, Arizona • Fort Smith, Arkansas • Encinitas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 2, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03812510
View directory record Official record
Conditions
Common Wart
Interventions
A-101
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
1 Year and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
46
States / cities
Mobile, Alabama • Glendale, Arizona • Fort Smith, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 2, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis

NCT02667275
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
A-101 Solution, Vehicle Solution
Drug · Other
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Sep 2, 2026, 4:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

NCT01986920
View directory record Official record
Conditions
Seborrheic Keratosis (SK)
Interventions
A-101 25%, A-101 32.5%, A-101 40%, A-101 Vehicle
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 2, 2026, 4:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Duration of Effects of Massage in Healthy Participants

NCT05317702
View directory record Official record
Conditions
Healthy, Pressure Pain Threshold, Massage
Interventions
Moderately Painful Massage
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Sep 2, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Study of A-101 for the Treatment of Seborrheic Keratosis

NCT02260180
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
A-101
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Portland, Oregon • Fort Washington, Pennsylvania • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Sep 2, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03687372
View directory record Official record
Conditions
Common Wart
Interventions
A-101, vehicle
Drug · Other
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
24
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 2, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

A Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03691831
View directory record Official record
Conditions
Common Wart
Interventions
Active, Vehicle
Drug · Other
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
24
States / cities
Glendale, Arizona • Fort Smith, Arkansas • Encinitas, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 2, 2026, 4:14 PM EDT
Recruiting Phase 2 Interventional

4D-710 in Adult Patients With Cystic Fibrosis

NCT05248230
View directory record Official record
Conditions
Cystic Fibrosis Lung
Interventions
4D-710
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 2, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

A Phase2 of A-101 Topical Solution in Subjects With Common Warts

NCT03210337
View directory record Official record
Conditions
Common Wart
Interventions
A-101 Topical Solution, A-101 Vehicle Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
8 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Scottsdale, Arizona • Rogers, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Sep 2, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra

NCT03224598
View directory record Official record
Conditions
Dermatosis Papulosa Nigra
Interventions
A-101 Topical Solution 40%
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Sep 2, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Safety Study of A-101 Solution

NCT02667288
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
A-101 Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 2, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Results available

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses

NCT03487588
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
A-101 Topical Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Fort Washington, Pennsylvania • Knoxville, Tennessee • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 2, 2026, 4:14 PM EDT